8-K: Waters Corporation and BD Biosciences & Diagnostic Solutions Announce $17.5 Billion Combination to Create Life Science and Diagnostics Leader

Waters Corporation and Becton, Dickinson and Company's Biosciences & Diagnostic Solutions business have entered into a definitive agreement to combine in a $17.5 billion Reverse Morris Trust transaction, aiming to create a leading life science and diagnostics company with an expanded market presence and significant synergy potential.

Summary

• Waters Corporation and BD's Biosciences & Diagnostic Solutions business will combine in a tax-efficient Reverse Morris Trust transaction valued at approximately $17.5 billion.
• The combined company is projected to have pro forma 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion.
• The transaction is expected to double Waters' total addressable market to approximately $40 billion, with an anticipated annual growth rate of 5-7%.
• Over 70% of the combined company's revenue is expected to be annually recurring, with over 80% of revenue derived from iconic market-leading brands.
• Anticipated annualized EBITDA synergies are approximately $345 million by 2030, including $200 million in cost synergies by year three and $290 million in revenue synergies by year five.
• The combined entity is expected to deliver mid-to-high single-digit revenue growth and mid-teens annualized adjusted EPS growth between 2025 and 2030, with adjusted EPS accretion in the first year post-closing.
• BD will receive a cash distribution of approximately $4 billion, and Waters is expected to assume approximately $4 billion of incremental debt.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook on the proposed transaction, emphasizing significant strategic benefits, substantial financial synergies, and an industry-leading growth trajectory for the combined entity. The language consistently highlights value creation, complementary strengths, and accelerated growth opportunities, with clear financial targets and accretion expectations.

Positives

• Creates an innovative life science and diagnostics leader with pioneering technologies and an industry-leading financial outlook.
• Strong strategic fit, increasing presence in multiple high-growth adjacencies.
• Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growth.
• Increases annual recurring revenue to over 70% and over 80% of revenue from iconic market-leading brands.
• Anticipates approximately $345 million in annualized EBITDA synergies by 2030, including $200 million of cost synergies by year three and $290 million of revenue synergies by year five.
• Delivers an industry-leading financial outlook with mid-to-high single-digit revenue growth, approximately 500 basis points of adjusted operating margin expansion, and mid-teens annualized adjusted EPS growth expected over five years.
• Transaction expected to be accretive to adjusted EPS in the first year post-closing.
• Brings together complementary technologies (liquid chromatography, mass spectrometry, flow cytometry, diagnostic solutions) to serve high-volume testing in attractive and regulated end-markets.
• Accelerates Waters' expansion into high-growth adjacent end-markets like bioseparations, bioanalytical characterization, and multiplex diagnostics.
• Allows application of Waters' proven execution model (instrument replacement, service plan attachment, e-commerce adoption, new product launches) to BD's Biosciences & Diagnostic Solutions business.
• BD will receive a cash distribution of approximately $4 billion, with at least half allocated to share repurchases and the remainder to debt repayment.
• Transaction is expected to be generally tax-free for U.S. federal income tax purposes to BD and BD's shareholders.

Negatives

• Waters is expected to assume approximately $4 billion of incremental debt, resulting in a net-debt-to-adjusted EBITDA leverage ratio of 2.3x at closing.
• Projected financial information for the combined businesses is based on management's estimates, assumptions, and projections and has not been prepared in conformance with Regulation S-X relating to pro forma financial information.

Risks

• One or more closing conditions, including certain regulatory approvals, may not be satisfied or waived on a timely basis or otherwise.
• A governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the Proposed Transaction, or may require conditions, limitations, or restrictions.
• Required approval by Waters' stockholders may not be obtained.
• The Proposed Transaction may not be completed on the terms or in the time frame expected, or at all.
• Unexpected costs, charges, or expenses may result from the Proposed Transaction.
• Uncertainty exists regarding the expected financial performance of the combined company following completion of the Proposed Transaction.
• Failure to realize the anticipated benefits of the Proposed Transaction, including as a result of delay in completing the Proposed Transaction or integrating the businesses.
• The combined company may face difficulties in implementing its business strategy.
• Difficulties and delays may occur in the combined company achieving revenue and cost synergies.
• Inability of the combined company to retain and hire key personnel.
• The occurrence of any event that could give rise to termination of the Proposed Transaction.
• Stockholder litigation or other litigation, settlements, or investigations may affect the timing or occurrence of the Proposed Transaction or result in significant costs of defense, indemnification, and liability.
• Evolving legal, regulatory, and tax regimes could impact the transaction or combined operations.
• Changes in general economic and/or industry-specific conditions or volatility resulting from tariffs.
• Actions by third parties, including government agencies, could affect the transaction.
• The anticipated tax treatment of the Proposed Transaction may not be obtained.
• Greater than expected difficulty in separating the business of SpinCo from the other businesses of BD.
• Disruption of management time from ongoing business operations due to the pendency of the Proposed Transaction.
• Other effects of the pendency of the Proposed Transaction on relationships with employees, customers, suppliers, or other counterparties.
• The credit ratings of the combined company could decline following the Proposed Transaction.
• The announcement or consummation of the Proposed Transaction could have a negative effect on the market price of the capital stock of Waters and BD or on Waters and BD's operating results.

Future Outlook

The combined company is expected to achieve mid-to-high single-digit revenue growth and mid-teens annualized adjusted EPS growth between 2025 and 2030, with approximately 500 basis points of adjusted operating margin expansion. By 2030, the pro forma combined company is projected to reach approximately $9 billion in revenue, $3.3 billion in adjusted EBITDA, and an adjusted operating margin of 32%.

Management Comments

• "This transaction marks a pivotal milestone in Waters' transformation journey as we embark on a new chapter of growth and value creation. As the Board of Directors evaluated this opportunity throughout the process, it became evident that combining with BD's Biosciences & Diagnostic Solutions business is an excellent strategic fit with complementary strengths. We are confident that this combination will accelerate our strategy in multiple high-growth markets and deliver substantial nearand long-term value to our shareholders." Flemming Ornskov, M.D., M.P.H., Chairman, Waters.
• "Waters' transformation, marked by strong commercial execution and revitalized innovation, positions us well for this exciting next chapter. We see tremendous opportunity to immediately apply our expertise in instrument replacement, service plan attachment, and eCommerce expansion, and realize the full potential of the flow cytometry and specialty diagnostics portfolios. The combination doubles our accessible market to approximately $40 billion and allows us to accelerate value creation in multiple high-growth adjacencies such as bioseparations, bioanalytical characterization, and multiplex diagnostics, while increasing the ratio of our annually recurring revenues. We are bringing together two pioneering organizations with a rich history of delivering breakthrough innovations driven by strong R&D investment and a common customer-centric culture. I look forward to welcoming our talented and like-minded colleagues from BD's Biosciences & Diagnostic Solutions business and leading the collective organization. Together, we will work to make this combination a resounding success for our stakeholders and deliver significant value for shareholders." Udit Batra, Ph.D., President and Chief Executive Officer, Waters.
• "We are bringing together complementary portfolios and channels that create an industry-leading life science and diagnostics company. We see an incredible opportunity to leverage both companies' commitments to unparalleled innovation, technology, and commercial presence to serve attractive high-growth end-markets, while simultaneously unlocking multiple new growth vectors. We couldn't be more confident that the combined company, under Udit's leadership, represents the best path to create substantial value for shareholders. Waters offers the right cultural fit for our Biosciences & Diagnostic Solutions associates to flourish and continue their legacy of developing new-to-world, innovative solutions that make a meaningful impact on global healthcare. This transaction is an important milestone for BD, as it enhances our strategic focus as a leading medical technology company. BD is committed to unlocking long-term value through continued investment in our strong innovation pipeline, and operational and commercial excellence that will drive durable and profitable growth." Tom Polen, Chairman, CEO and President, BD.

Industry Context

This combination creates a significant new player in the life science tools and diagnostics industry, bringing together Waters' expertise in analytical instruments (liquid chromatography, mass spectrometry) with BD's strengths in flow cytometry and diagnostic solutions. The transaction aims to capitalize on high-growth adjacencies such as bioseparations, bioanalytical characterization, and multiplex diagnostics, expanding the combined entity's total addressable market to $40 billion. This strategic move reflects a broader industry trend towards consolidation and the pursuit of integrated solutions that span research, clinical diagnostics, and quality control in regulated environments.

Comparison to Industry Standards

• The combined company's expected pro forma adjusted operating margin of 32% by 2030 is described as "industry-leading."
• Waters' standalone FCF as % of revenue (37% in CY24) is significantly higher than the peer average of 18% (peers listed as A, AVTR, DHR, RVTY, TMO).
• Waters' standalone adjusted operating margin (31% in CY24) is higher than the peer average of 27% (peers listed as A, AVTR, DHR, RVTY, TMO).
• BD Biosciences/Diagnostics is noted as a leader in upstream and clinical software, with over 40,000 installed base in flow cytometry and over 25,000 in microbiology molecular diagnostics.
• Waters' Empower informatics platform is used for approximately 80% of novel drugs submitted to FDA, EMA, China NMPA.
• Waters is ranked #1 by customers for service satisfaction among instrument vendors (SDi 2024 Analytical & Life Science Instrumentation Service Market) and has a tNPS score over 20 points higher than benchmark average (TSIA 2024).

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders (Waters): Expected to own approximately 60.8% of the combined company, with anticipated adjusted EPS accretion in the first year and mid-teens annualized adjusted EPS growth over five years, suggesting significant value creation.
• Shareholders (BD): Expected to own approximately 39.2% of the combined company and BD will receive a $4 billion cash distribution, with a commitment to use at least half for share repurchases, enhancing capital allocation.
• Employees: Waters will welcome talented and like-minded colleagues from BD's Biosciences & Diagnostic Solutions business. Risk of inability to retain and hire key personnel is mentioned.
• Customers: The combination aims to bring best-in-class technologies, enhanced market access, improved service support, accelerated menu expansion, and automation for multiplex diagnostics, suggesting improved offerings and support.
• Suppliers/Counterparties: Risk of disruption to business, contractual, and operational relationships due to the pendency of the transaction is mentioned.
• Creditors: Waters is expected to assume approximately $4 billion of incremental debt, resulting in a net-debt-to-adjusted EBITDA leverage ratio of 2.3x at closing, which could impact credit risk perception.

Next Steps

• File relevant materials with the SEC, including a registration statement on Form S-4 by Waters (including a preliminary and definitive proxy statement/prospectus) and a registration statement on Form 10 by SpinCo.
• Obtain required regulatory approvals.
• Obtain Waters shareholder approval.
• Satisfy other customary closing conditions.
• Joint conference call and webcast at 8:00 a.m. ET on July 14, 2025, to discuss the Proposed Transaction.
• Waters and BD directors and executive officers may be considered participants in the solicitation of proxies from Waters stockholders.
• Executives from both companies will serve in key leadership roles to be announced at a later date.

Key Dates

Recommendation

Keywords

Waters Corporation, Becton Dickinson, BD, Biosciences, Diagnostic Solutions, Merger, Acquisition, Reverse Morris Trust, Life Science, Diagnostics, Mass Spectrometry, Liquid Chromatography, Flow Cytometry, Molecular Diagnostics, Synergies, SEC Filing, 8-K, Healthcare Technology, Analytical Instruments, Laboratory Equipment